FDA Approves Gilead's Yeztugo As First Twice-Yearly Injectable PrEP For HIV Prevention
19/6 04:09
(RTTNews) - Gilead Sciences Inc. (GILD) announced that the U.S. Food and Drug Administration has approved Yeztugo (lenacapavir)-the company's injectable HIV-1 capsid inhibitor-as pre-exposure prophylaxis or PrEP to reduce the risk of sexually acquired HIV in adults and adolescent...